🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just published in Journal of Clinical Oncology the updated ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues OncoAlert Ann Partridge MD, MPH Oncofertility Link: ascopubs.org/doi/10.1200/JC…

Watch our interview with Mrinal Patnaik (Mayo Clinic) from #IBC2025 to learn about the difference between age-related clonal hematopoiesis and context-relevant CH. Click here for the interview: 👉 ow.ly/BsSX50VkCIi 👈 #HemOnc #Leusm #AMLsm

Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific membrane antigen therapy pubmed.ncbi.nlm.nih.gov/40176753/ #Lutetium #CH #PPM1D #TP53 #prostate yael kusne MD PhD Mayo Clinic Comprehensive Cancer Center

The FY26 HHS Budget in Brief has been released. It outlines how the existing NIH institutes & centers will be combined into eight (with only NCI, NIA & NIAID retaining their original structure). There are 40% cuts proposed in NIH budget (including the NCI). 😢 Cancer Research 📉

Vasculitis associated with VEXAS syndrome. pubmed.ncbi.nlm.nih.gov/39392442/ Mayo Clinic #VEXAS

Delighted to have our work on Polygenic Modifiers of #TelomereBiologyDisorders, led by Michael Poeschla, along with Sasha Gusev, Mitchell Machiela, Sharon A. Savage, M.D., Tummala H, and others, published as an advanced online paper in Journal of Clinical Investigation today:

Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. pubmed.ncbi.nlm.nih.gov/40040251/ #CH #CCUS #R525H

Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk? pubmed.ncbi.nlm.nih.gov/40446156/ Mayo Clinic

A mutant ASXL1-BAP1-EHMT complex contributes to heterochromatin dysfunction in clonal hematopoiesis and chronic mon… pubmed.ncbi.nlm.nih.gov/39752521/ #CH #CMML #ASXL1

Thrilled to begin a new chapter at BCM! Alongside developing a CHIP clinic, I will continue research on how CH becomes MDS/AML, and how to stop it! 🙌🏻 Grateful to join the Texas Medical Center community and work with truly inspiring women in science Peggy Goodell and Katherine King MDPhD

A striking example of human genetics-driven molecular discovery. A GWAS of Yersinia pestis infection in 1,000 B cell lines identified a missense variant (rs2282284) in FCRL3—a B cell membrane protein—strongly associated with protection against infection. It turns out that FCRL3

stop by our poster this eve at #EHA2025 PS1620 Guillermo Montalban-Bravo will present our work on refining the Dx criteria for Oligomonocytic CMML We’ve developed a predictive model, stop by & see the details. A fantastic collaborative effort w/ Mrinal Patnaik JJ rodriguez-sevilla

#EHA2025 #EHA25 #PPM1D #TP53 Do visit our poster, highlighting the prevalence and clinical correlates of PPM1Dm in therapy-related #clonal_hematopoiesis #clonal_cytopenia Key takeaways: 1. In one of the largest cohorts, PPM1Dm +/- TP53m were significantly enriched in therapy

With the disappointing announcement today by AbbVie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia #CMML #TET2 Clifford Csizmar Mayo Clinic Comprehensive Cancer Center MD Anderson Cancer Center pubmed.ncbi.nlm.nih.gov/40555734/

RAS Mutation Identifies a Poor Prognostic Molecular Subtype of Therapy-Related Myeloid Neoplasm - PubMed ⁦Mayo Clinic Comprehensive Cancer Center⁩ #RAS pubmed.ncbi.nlm.nih.gov/40402688/

Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia - PubMed ⁦MD Anderson Cancer Center⁩ ⁦Mayo Clinic Comprehensive Cancer Center⁩ ⁦Blood Journals Portfolio⁩ GMB ⁦Sanam Loghavi, MD صنم لغوی 🔬🧬⁩ ⁦Naveen Pemmaraju, MD⁩ ⁦Clifford Csizmar⁩ #CMML #RAS pubmed.ncbi.nlm.nih.gov/40644618/

When it comes to TET2 mutations in CMML, more are better! Multiple TET2 mt offset the negative impacts of ASXL1 and RAS mutations in myelodysplastic and myeloproliferative CMML, respectively. Mrinal Patnaik nature.com/articles/s4137…

Delighted to collaborate on this study led by Jie Liu Kelly Bolton MD PhD describing how germline genetic variation influences the trajectory of clonal hematopoiesis to hematologic malignancy nature.com/articles/s4158… Nature Genetics

Clonal haematopoiesis to clonal cytopenias: unravelling disease evolut... sciencedirect.com/science/articl… The Lancet Haematology Kristina Kirschner Yael Kusne Catherine Cargo #CH #CCUS #Agerelated #Contextrelevant Mayo Clinic Comprehensive Cancer Center Mayo Clinic